ByTrending Posts
Do Wegovy Pricing Pathways in 2026 Signal a…
Global – December 2025 — A new pricing and access analysis for Wegovy (semaglutide) highlights how multiple reimbursement…
Does FDA Approval of Nereus Mark a Long-Awaited…
Washington, D.C. – December 2025 — Vanda Pharmaceuticals achieved a major regulatory milestone after the U.S. Food and…
Will Axsome Therapeutics’ FDA Priority Review of AXS-05…
New York – December 31, 2025 — Axsome Therapeutics has reached a major regulatory milestone after the U.S.…
Can Dual Regulatory Approvals Position UltraGreen.ai as a…
Singapore – December 31, 2025 — UltraGreen.ai Limited, a Singapore-based company specializing in fluorescence-guided surgery and digital health…
What Does SoftBank’s $41 Billion Bet on OpenAI…
Global – December 2025 — SoftBank’s $41 billion investment in OpenAI represents one of the most consequential capital…
Did Ophthalmic Therapy Approvals in 2025 Redefine Vision…
Global – December 2025 — The ophthalmology therapeutic area entered a renewed phase of innovation in 2025, driven…
Did Metabolic Therapy Approvals in 2025 Reset the…
Global – December 2025 — The metabolic therapeutic area emerged as one of the most transformative forces in…
Did Renal Therapy Approvals in 2025 Redefine Kidney…
Global – December 2025 — The renal therapeutic area emerged as a renewed focus of innovation in 2025,…
Did Cardiovascular Approvals in 2025 Signal a New…
Global – December 2025 — The cardiovascular (CV) therapeutic area re-emerged as a strategic growth engine in 2025,…
Trending Posts
Latest Stories
Is “ChatGPT for Doctors” Driving OpenEvidence’s $12 B Valuation Surge?
January 26, 2026 | AI in Healthcare | Strategic Investment & Market Expansion OpenEvidence, the…
Can GSK’s New Leadership Translate into Multi-Franchise Growth in 2026?
Late January 2026 | Full-Year 2025 Earnings Preview | Vaccines, Immunology & Specialty Care GlaxoSmithKline…
Can Gilead Sustain Growth Beyond HIV and Hepatitis in 2026?
Late January 2026 | Full-Year 2025 Earnings Preview | Antivirals, Oncology & Emerging Therapies Gilead…
Is AstraZeneca Building the Most Diversified Growth Engine in Global Pharma?
Late January–Early February 2026 | Full-Year 2025 Earnings Preview | Oncology, CVRM & Platform Innovation…
Gallery
